Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5378 | 2021 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2793 | 2020 |
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1688 | 2020 |
Real-time, portable genome sequencing for Ebola surveillance J Quick, NJ Loman, S Duraffour, JT Simpson, E Severi, L Cowley, JA Bore, ... Nature 530 (7589), 228-232, 2016 | 1503 | 2016 |
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1354 | 2021 |
Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1145 | 2021 |
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial … AM Henao-Restrepo, A Camacho, IM Longini, CH Watson, WJ Edmunds, ... The Lancet 389 (10068), 505-518, 2017 | 1074 | 2017 |
Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples J Quick, ND Grubaugh, ST Pullan, IM Claro, AD Smith, K Gangavarapu, ... Nature protocols 12 (6), 1261-1276, 2017 | 1067 | 2017 |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 941 | 2022 |
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial AM Henao-Restrepo, IM Longini, M Egger, NE Dean, WJ Edmunds, ... The Lancet 386 (9996), 857-866, 2015 | 888 | 2015 |
Animal models for COVID-19 C Muñoz-Fontela, WE Dowling, SGP Funnell, PS Gsell, AX Riveros-Balta, ... Nature 586 (7830), 509-515, 2020 | 810 | 2020 |
Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum C Liu, HM Ginn, W Dejnirattisai, P Supasa, B Wang, A Tuekprakhon, ... Cell 184 (16), 4220-4236. e13, 2021 | 757 | 2021 |
Immunogenicity of a DNA vaccine candidate for COVID-19 TRF Smith, A Patel, S Ramos, D Elwood, X Zhu, J Yan, EN Gary, ... Nature communications 11 (1), 2601, 2020 | 667 | 2020 |
Antibody evasion by the P. 1 strain of SARS-CoV-2 W Dejnirattisai, D Zhou, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (11), 2939-2954. e9, 2021 | 666 | 2021 |
gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand WW Overwijk, A Tsung, KR Irvine, MR Parkhurst, TJ Goletz, K Tsung, ... The Journal of experimental medicine 188 (2), 277-286, 1998 | 597 | 1998 |
Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea D Sissoko, C Laouenan, E Folkesson, AB M’lebing, AH Beavogui, S Baize, ... PLoS medicine 13 (3), e1001967, 2016 | 579 | 2016 |
Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T … WW Overwijk, DS Lee, DR Surman, KR Irvine, CE Touloukian, CC Chan, ... Proceedings of the National Academy of Sciences 96 (6), 2982-2987, 1999 | 548 | 1999 |
Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (8), 2201-2211. e7, 2021 | 491 | 2021 |
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 J Huo, A Le Bas, RR Ruza, HME Duyvesteyn, H Mikolajek, T Malinauskas, ... Nature structural & molecular biology 27 (9), 846-854, 2020 | 489 | 2020 |
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line MW Carroll, B Moss Virology 238 (2), 198-211, 1997 | 455 | 1997 |